[The value of the internal capsule signs in the stimulation of the subthalamic nucleus in Parkinson's disease]

Rev Neurol. 2005 Aug;41(4):193-7.
[Article in Spanish]

Abstract

Introduction: The effectiveness of stimulating the subthalamic nucleus (DBS-STN) in advanced Parkinson's disease (PD) largely depends on the correct placement of the electrodes. Since the sensory-motor region of the STN lies beside the internal capsule (IC), we believe that the motor effectiveness of DBS-STN could be related to the stimulation threshold in which IC signs appear (IC threshold).

Patients and methods: An examination of 17 consecutive patients with advanced PD who had been submitted to bilateral DBS-STN (one case was unilateral) was carried out to determine the motor improvement on each side of the body (n = 33) and the energy consumption one year after surgery according to the IC threshold obtained during the programming.

Results: A 45% improvement was observed in the UPDRS III in off and there was a 24% reduction in the equivalent dose of levodopa with bilateral DBS-STN. When the electrodes were considered, there was a statistically significant improvement that depended on the IC threshold. Energy consumption differed significantly between electrodes with an IC threshold of 3-7 V (1.5 +/- 1.2 microW) and those with an IC threshold > 7 V (8.3 +/- 9.4 microW).

Conclusions: During the stimulation phase and following the correct location of the STN, which was achieved by neurophysiological recording, the IC threshold has prognostic implications in medium-long term motor effectiveness and in the consumption of the battery in the generator.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use
  • Deep Brain Stimulation* / instrumentation
  • Deep Brain Stimulation* / methods
  • Electrodes, Implanted
  • Female
  • Humans
  • Internal Capsule / physiology
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Parkinson Disease / physiopathology
  • Parkinson Disease / therapy*
  • Subthalamic Nucleus / physiology*
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Levodopa